AP Pelvis X-ray Interpretation

Technique

Findings

LEFT HIP - Major Pathology

• Fracture-dislocation of the left hip: The left femoral head is severely deformed, fragmented, and displaced superiorly and laterally out of the acetabular cup - consistent with posterior/superior dislocation
• Comminuted fracture through the left femoral neck/intertrochanteric region with complete displacement
• Associated left acetabular disruption - the acetabular roof and posterior wall appear involved, suggesting a complex fracture-dislocation pattern
• Marked osteopenia of the left proximal femur and hemipelvis (likely disuse atrophy or chronic pathology)

RIGHT HIP

• Femoral head spherical and well-seated in the acetabulum
• Mild superior joint space narrowing
• Mild subchondral sclerosis of the acetabular roof - consistent with early osteoarthritis
• No acute fracture or dislocation

Pelvis / Pubic Symphysis / SI Joints

• Pubic symphysis is aligned; no diastasis
• Bilateral SI joint sclerosis and mild narrowing, more pronounced on the left - likely reactive
• No clear isolated pubic rami fractures identified, though pelvic tilt from left hip displacement alters geometry

Lumbar Spine

• L4-L5 visible with mild marginal osteophytes and disc space narrowing - degenerative changes

Soft Tissue

• Large oval radiolucency overlying the lower sacrum/coccyx - rectal gas shadow, not a bony lytic lesion

Summary of Key Findings

Clinical Impression

Recommendations

1. Urgent orthopedic surgery consultation
2. CT pelvis with 3D reconstruction - to fully characterize acetabular fracture pattern, assess pelvic ring stability, and plan surgical approach
3. Assess neurovascular status of left lower limb (sciatic nerve injury risk with posterior hip dislocation)
4. Surgical options to discuss: open reduction and internal fixation (ORIF) vs. total hip arthroplasty, depending on patient age, bone quality, and chronicity

⚠️ This interpretation is provided for educational/clinical support purposes. Final radiological diagnosis should be confirmed by a qualified radiologist and treating orthopedic surgeon.

Hepatitis A (HAV)

1. Virology

• 27 nm, non-enveloped, icosahedral nucleocapsid
• Positive-sense, single-stranded RNA genome (~7.4-7.5 kb)
• Capsid made of 4 proteins: VP1, VP2, VP3, VP4 - VP1 is the spike that binds host cell receptor (α2-macroglobulin)
• Only one serotype (multiple genotypes: I, II, III; genotype I predominates worldwide)
• Replicates in the cytoplasm via RNA-dependent RNA polymerase
• Resists inactivation; stable at -20°C and low pH
• Formerly called "infectious hepatitis" or "short-incubation hepatitis"

2. Epidemiology & Transmission

• Worldwide distribution - endemic in Asia, Africa, Middle East, Central/South America
• Seroprevalence ranges from ~13% (Sweden) to ~100% (poor sanitary conditions)
• Primary route: Fecal-oral - contaminated food/water, person-to-person contact
• High-risk groups:
  • Travelers to endemic countries
  • Children in day care centers (and their parents)
  • Men who have sex with men
  • Injection drug users / homeless persons
  • Hemophilia patients receiving plasma products
  • Health care workers
• Blood transfusion transmission is possible but uncommon
• No chronic carriage - does not cause chronic infection

3. Pathogenesis

1. Replicates in intestinal mucosa (incubation 15-45 days)
2. Enters viremia → spreads to liver
3. In the liver: causes lymphoid cell infiltration, hepatocyte necrosis, and Kupffer cell proliferation
4. Virus is secreted into bile → shed in stool (major infectious route)
5. Cell lysis releases virions

4. Clinical Features

• Incubation period: 15-45 days (mean ~1 month)
• Up to 50% of infections are subclinical in children; symptomatic cases increase with age

• Fever, anorexia, nausea, vomiting
• Right upper quadrant pain
• Fatigue, malaise

• Jaundice
• Dark urine (bilirubinuria) - appears before jaundice
• Clay/pale-colored stools
• Pruritus (if cholestatic)

• Relapsing hepatitis A - most common cause of relapsing cholestatic hepatitis
• Prolonged course (6-9 months) in ~10% of adults
• Hospitalization required in up to 13% of adult cases

5. Serological Markers & Timeline

• IgM anti-HAV disappears in 4-12 months
• IgG anti-HAV persists lifelong - protective immunity

6. Diagnosis

• Definitive: IgM anti-HAV by enzyme immunoassay (EIA) - the diagnostic standard for acute infection
• HAV RNA by PCR (stool/serum) - not routinely needed
• LFTs: elevated ALT, AST, bilirubin
• "Total anti-HAV" (detects both IgM + IgG) - used to assess immunity/vaccination status, not acute diagnosis
• Only test symptomatic individuals with IgM (false positives occur in asymptomatic)

7. Treatment

• No specific antiviral treatment - infection is self-limited
• Supportive care: rest, hydration, nutrition
• Hospitalization for severe cases
• Liver transplantation is the only option for fulminant acute liver failure (rare)
• Avoid hepatotoxic drugs and alcohol

8. Prognosis

• Typically resolves in 3-4 weeks without complications
• Never progresses to chronic infection (key differentiator from HBV/HCV)
• Fulminant hepatitis A: <0.1% of cases, but risk and mortality increase with age
  • Mortality: 1.8% in patients >50 years
  • 4% of all fulminant hepatitis cases in the US are HAV
• Superinfection with HAV in chronic HBV patients: 6-23x higher morbidity/mortality
• Poor prognosis indicators: Factor V <40%, signs of encephalopathy, worsening jaundice, ascites, acute liver shrinkage

9. Prevention & Vaccination

• Two-dose schedule: Day 0 and 6-18 months later
• Accelerated schedule (for travelers): Days 0, 7, 21
• Virtually 100% seroconversion in healthy individuals
• Combined HAV+HBV vaccine is available
• Protective titers persist: at least 27 years after vaccination
• Post-vaccination IgG titers remain detectable in ~99% at 5 years

• Travelers to endemic areas
• MSM (men who have sex with men)
• Injection drug users
• Healthcare professionals
• Patients with chronic liver disease
• Close contacts of HAV cases
• Children as part of childhood immunization programs

• Both HAV vaccine and immunoglobulin (IG) are ~98% effective for PEP
• Vaccination preferred (also prevents secondary cases)
• Often used together in PEP settings

Summary Comparison with other Hepatitis Viruses